ArticleHeart rhythm O22026
Difference in the efficacy of atrial antitachycardia pacing for suppression of ventricular arrhythmias.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intermittent atrial tachyarrhythmias (ATAs) are associated with ventricular arrhythmias (VAs), particularly in patients with left ventricular dysfunction. Little is known about the effect of atrial antitachycardia pacing (ATP) (reactive ATP [rATP]) on the reduction of VAs in patients with a shock device. Objective: We examined differences in the efficacy of rATP in the suppression of VAs in patients with a shock device. Methods: Overall, among 589 consecutive patients with a shock device, we analyzed those with a history of intermittent ATAs and a cardiac resynchronization therapy with a defibrillator (CRTD n = 112) or an implantable cardioverter-defibrillator (ICD) (n = 32). The study subjects were categorized into 2 groups based on the availability of rATP (rATP group 72 patients; no-rATP group 72 patients). The primary outcome was VA events that were treated by ventricular ATP or shock or lasted ≥30 seconds. Results: During a median follow-up of 862 days, the rATP group (n = 55) had a significantly lower risk of VAs than the no-rATP group (n = 57) (log-rank Conclusion: rATP was significantly associated with a lower risk of VAs in patients with CRTD and intermittent ATAs, but not in patients with an ICD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.